Placental Isozyme Research Articles

Comparative analysis of cell surface antigens expressed by cell lines derived from human germ cell tumours

The pattern of cell surface antigen expression of a set of cell lines derived from human germ cell tumours and corresponding to various cell phenotypes found within these tumours was studied using immunofluorescence. Twenty-two different antibodies were used. Many of these antibodies have been noted to recognise epitopes that are either preferentially expressed by embryonal carcinoma (EC) cells, or by more differentiated cell types. Using scatter plots and rank correlations, 6 groups of antibodies were distinguished with respect to their staining patterns on the cell lines tested. Several antibodies showed a specific staining pattern in relation to the differentiation state of the cells. Two groups of antibodies included those recognising high m.w. glycoproteins (antibodies TRA-1-60, TRA-1-81, GCTM2, 3-177, K4 and K21) and the ganglioseries glycolipid antigens SSEA-3 and -4 (antibodies MC631 and MC813-70). These antibodies mostly stained EC cells but not other cell types, confirming previously published data. However, one of these groups, comprising antibodies K4 and MC631, was more exclusively associated with the EC cell phenotype than was the other group. Antibodies recognising the liver isozyme of alkaline phosphatase (TRA-2-49 and TRA-2-54) also reacted strongly with most EC cell lines, although they reacted significantly with a number of other cell lines as well, whereas antibodies to the placental isozyme tended to react only weakly with EC cells. The antibodies recognising the ganglioseries glycolipids GD2 and GD3 (VIN2PB22 and VINIS56) preferentially stained cells with neuroectodermal characteristics. Other antibodies showed a heterogeneous staining pattern for the cell lines with different phenotypes. The data obtained from the cell lines were, in general, similar to data obtained from immunohistochemical studies on tissue sections of primary germ cell tumours of the adult testis, including carcinoma in situ.

Comparison of experimental and theoretical parameters of the moolgavkar-venzon-knudson incidence function for the stages of initiation and promotion in rat hepatocarcinogenesis

Mathematical descriptions of complex biological phenomena, such as cancer, require an experimental format that faithfully recapitulates the biological process. In addition, the biological process must dictate the parameters in the mathematical formula. Evidence from the epidemiology of several human cancers and from experimental carcinogenesis in several organ systems indicates that cancer is a multistage process. The initiation-promotion-progression format of experimental carcinogenesis mimics the development of cancer in humans and other animals. In rats, the altered hepatic focus model of hepatocarcinogenesis has been well characterized and, coupled with the method of quantitative stereology, permits accurate determination of the number and the volume fraction of such altered foci per liver. The placental isozyme of glutathione S-transferase (PGST) is reportedly the best single marker of preneoplasia in the rat liver. Recently, single hepatocytes expressing PGST have been proposed as putatively initiated cells. Quantitation of individual hepatic cells and altered hepatic foci expressing PGST in the livers of rats subjected to an initiation-promotion protocol permits determination of the congruence of the Moolgavkar-Venzon-Knudson (MVK) model with experimental data. The best fit of the MVK model for the preneoplastic stages of hepatocarcinogenesis assumes that all hepatocytes are susceptible and that single hepatocytes expressing PGST are the initiated cell population for the focal lesions that express PGST. Further refinement of the initiation-promotion-progression model to permit accurate quantitation of early malignant conversion should allow a more complete analysis of the congruence of the MVK model for human cancer risk determination. In addition, the MVK model may be extended to other model systems and to human cancers in which early preneoplasia can be quantitated. Furthermore, the use of a more biologically based risk-assessment protocol, such as the MVK model rather than the stochastic one-hit model presently used, would permit incorporation of the present knowledge on the pathogenesis of cancer. To apply experimental data to a mathematical model that reflects the biological processes underlying human cancer development will require integration of the cell kinetics and experimental data to a mathematical model that reflects the biological processes underlying human cancer development including the pharmacokinetic and pharmacodynamic properties of the treatment chemicals.

The quantitation of altered hepatic foci during multistage hepatocarcinogenesis in the rat: Transforming growth factor α expression as a marker for the stage of progression

The experimental three-stage hepatocarcinogenesis protocol of initiation, promotion, and progression, coupled with the analytical technique of stereology, permits quantitative analysis of the carcinogenic process, including the derivation of biologically based risk assessment models. The aberrant expression of the placental isozyme of glutathione S-transferase (PGST) is an efficient marker for initiated, preneoplastic, and neoplastic hepatocytes. Putatively initiated cells and their clonal progeny can be identified, enumerated, and their growth characteristics determined on the basis of their aberrant expression of this protein. A lack of suitable markers has made the identification and quantitation of hepatocytes in the early stage of progression more difficult. One characteristic of cells in the stage of progression is the evolution of relatively autonomous growth. The alteration of growth factor signalling pathways may provide one mechanism for this observation. The expression of transforming growth factor α (TGFα) is seen in many malignancies. The initiation-promotion-progression protocol has been used to induce progression in the rat liver. The focal expression of TGFα was found to correlate with areas of progression in rats subjected to this protocol. The ability to identify and quantitate cells in the stage of progression should facilitate application of the Moolgavkar-VenzonKnudson model for assessing human risk from carcinogens active at each of these three stages. Validation of this model will require determination of the number and growth characteristics of hepatocytes in the stage of progression.

Determination of alkaline phosphatase isozymes in amniotic fluid.

A simple method for the determination of the three isozymes of alkaline phosphatase (EC 3.1.3.1) contained in amniotic fluid (fetal intestinal, placental, and liver-bone-kidney) is presented. Total alkaline phosphatase activity was assayed in 10,000 g supernatants of amniotic fluid from 30 normal women between the 16th and 20th week of pregnancy. Electrophoretic patterns and inhibition by L-phenylalanine and L-homoarginine studies showed that all the fetal intestinal isozyme was precipitated in the pellet after centrifugation at 100,000 g for 90 min. Thus, the difference between total alkaline phosphatase activity and activity in the 100,000 g supernatant corresponds to fetal intestinal alkaline phosphatase. Placental isozyme can be determined by assaying alkaline phosphatase in the 100,000 g supernatant after heating at 56 degrees C for 90 min. Liver-bone-kidney isozyme activity is obtained by subtracting placental alkaline phosphatase activity from that of the 100,000 g supernatant. Mean percentages of the total alkaline phosphatase for each of the isozymes in amniotic fluid were 81% for fetal intestinal alkaline phosphatase, 7.5% for placental alkaline phosphatase and 12.0% for liver-bone-kidney alkaline phosphatase. Determination of fetal intestinal alkaline phosphatase by this method could be applied to the diagnosis of cystic fibrosis in fetuses having a 1:4 risk of being affected.

Biochemical events during initiation of rat hepatocarcinogenesis.

Carcinogenesis is a multistep, multistage process that begins with irreversible, but heritable damage to a single cell. The partial hepatectomy/diethylnitrosamine (DEN) model of rat hepatocarcinogenesis has been well characterized and many aspects of the stage of initiation are known. Recently, it has been suggested that hepatocytes expressing the placental isozyme of glutathione S-transferase (PGST) may be one population of initiated cells. Male Fischer rats were subjected to a 70% partial hepatectomy and at the peak of cell proliferation 24 h later were administered either the solvent trioctanoin, or 10 mg DEN/kg. The rats were administered 100 mg bromodeoxyuridine (BrdU)/kg 1 h prior to death at various times after DEN administration. Since initiation of the carcinogenesis process requires the division of cells containing DNA damage to induce mutations, we examined the concentration of alkylated adducts and the labeling index at various times after DEN administration. In addition, the time course of hepatic PGST expression was determined concurrent with the adduct concentration and labeling index. During the first day after DEN or solvent administration to a rat subjected to a 70% partial hepatectomy, a diurnal variation in labeling index was observed. A recovery to postsurgical labeling index levels was demonstrated for both the solvent- and DEN-treated groups by 7 days. The concentration of three promutagenic lesions was maximal at 6 h after DEN administration. The detectable level of the O6EG adduct was negligible by 24 h after DEN administration, while the two O-alkylpyrimidines, O2ET and O4ET, were retained for much longer periods. Single hepatocytes expressing PGST were observed by 2 days after DEN administration, while small foci of PGST-expressing hepatocytes could be reliably detected by 2 weeks. Two phases of PGST expression in single hepatocytes were observed. The first phase was maximal at day 3 and complete by day 6, while the second reached a plateau by day 8 and was maintained for the 28 days of the study. The presence of the three O-alkylation adducts during a time of enhanced cellular proliferation suggests that all three promutagenic adducts may contribute to the initiation that results in the partial hepatectomy/DEN model of rat hepatocarcinogenesis.

Focal and non-focal hepatic expression of placental glutathione S-transferase in carcinogen-treated rats.

Carcinogenesis develops in stages that have been operationally defined as initiation, promotion and progression. Although morphological end points have been described for detection and quantitation of these stages, to date initiation has been assessed only in the context of clonal growth in response to certain promoting agents. Initiated cells are morphologically indistinguishable from surrounding cells and early changes at the cellular level during initiation have not been clarified. One commonly used end point for the detection of preneoplastic hepatic lesions i their aberrant expression of the placental isozyme of glutathione S-transferase (PGST). Because single hepatocytes expressing PGST have been detected in aged rats and in those administered hepatocarcinogens, it has been suggested that such cells constitute a population of putatively initiated hepatocytes. In order to further elucidate the characteristics of single PGST-positive hepatocytes, we analyzed the number of these cells 2 and 18 weeks after various doses (0-100 mg/kg) of diethylnitrosamine (DEN) and of dimethylbenz[a]anthracene (DMBA). When determined 14 days after carcinogen administration, the number of single hepatocytes expressing PGST was greater after DEN administration (ranging from 0.8 +/- 0.3 per cm2 transection of liver at 1 mg/kg to 33.0 +/- 4.7 at 100 mg/kg) than after DMBA administration (ranging from 0.25 +/- 0.14 at 10 mg/kg to 3.03 +/- 0.5 at 100 mg/kg); none were detected in control rats of the same age. Additional rats were maintained on a basal diet or a basal diet plus phenobarbital for a further 4 month period. Whereas individual PGST-positive hepatocytes were only sporadically detected in rats treated with DMBA and maintained on a basal diet for 18 weeks, those rats placed on phenobarbital for 16 weeks had an even higher number of such PGST-positive hepatocytes than at 2 weeks after DMBA administration. In contrast, the dose-response curve observed for DEN-treated rats 18 weeks after carcinogen administration was similar to that observed 2 weeks after carcinogen treatment for both phenobarbital- and non-phenobarbital-treated rats. In addition, the number of single PGST-positive hepatocytes detected at 2 weeks was directly parallel to the number of altered hepatic foci expressing PGST 18 weeks after DEN administration. The dose-dependent induction of PGST-positive single hepatocytes after treatment with two hepatocarcinogens, the dose-dependent growth of altered hepatic foci (AHF) expressing PGST with phenobarbital administration and the parallel dose-response curve of single hepatocytes expressing PGST and later of AHF expressing PGST argue strongly for a precursor role of single PGST-positive cells in the development of AHF expressing PGST.

Quantitative Comparison of Initiation and Mutation Phenotypes in Hepatocytes of the Analbuminemic Rat

The potential relationship between mutagenesis and carcinogenesis has been examined in the Nagase analbuminemic rat treated with a single dose of benzo[a]pyrene, an incomplete liver carcinogen. The apparent mutation rate at the albumin locus was calculated by determining the number of hepatocytes expressing a cross‐reactive product of albumin in analbuminemic rats treated with benzo[a]pyrene. The rate of initiation, the first stage in carcinogenesis, was determined by assessing the number of hepatocytes expressing the placental isozyme of glutathione S‐transferase (PGST) after administration of benzo[a]pyrene. Since the expression of PGST may represent hepatocellular changes independent of initiation, promotion with phenobarbital was employed to clonally expand those putatively initiated hepatocytes expressing PGST. With immunohistochemical measures to assess changes in albumin expression, a threefold increase in the number of hepatocytes expressing albumin was detected after administration of benzo[a]pyrene in Nagase analbuminemic rats. A more than five‐fold increase in altered hepatic foci (AHF) exhibiting increased PGST expression was observed in animals given benzo[a]pyrene treatment followed by phenobarbital, compared with those given benzo[a]pyrene alone. The number of albumin‐expressing single hepatocytes detected was of the same order of magnitude as the number of individual hepatocytes and AHF expressing PGST, suggesting that similar events may be involved in their formation. Since 3 × 106 single hepatocytes expressing albumin were found in the analbuminemic rat liver after a single administration of benzo[a]pyrene, while less than 2 × 104 AHF expressing PGST were observed, formation of individual hepatocytes expressing albumin was a far more frequent event than clonal expansion of initiated hepatocytes in the Nagase analbuminemic rat. However, the number of loci of PGST expression including AHF and single hepatocytes is comparable to that of single hepatocytes expressing albumin.

The effect of the dose of diethylnitrosamine on the initiation of altered hepatic foci in neonatal female rats.

The dose-response characteristics of initiation of hepatocarcinogenesis by diethylnitrosamine (DEN) was investigated in the neonatal female rat by means of the quantitative stereologic estimation of altered hepatic foci (AHF) expressing multiple markers. At 5 days of age, female Sprague-Dawley rats were given a single i.p. dose of DEN (0.1-30 mg/kg body wt) or the vehicle (trioctanoin). The semisynthetic AIN-76A diet was provided to half of the rats in each treatment group, while the remainder received this diet containing 500 mg phenobarbital (PB)/kg for 8 months from weaning until the animals were killed. To ascertain more exactly the dose-response relationship for initiation by DEN, the number, volume percentage and phenotypes of the resulting AHF were determined by quantitative stereological analysis on serial sections of frozen tissue, each stained for one of four markers of preneoplasia. A linear relationship was observed between the dose of DEN (0-30 mg/kg) and the number and volume percentage of AHF detected, with each single marker or the total number of AHF detected when the placental isozyme of glutathione S transferase, gamma-glutamyl transpeptidase (GGT), canalicular adenosine triphosphatase, or glucose-6-phosphatase was used as the marker. For each dose, PB administration increased the number and volume of AHF scored compared with similarly initiated rats that did not receive a promoting stimulus. This was, in part, owing to enhanced GGT expression in AHF with PB administration. Promotion by PB resulted in a distribution of AHF phenotypes altered from that observed in rats not receiving PB. Initiation of AHF in neonatal female rats by DEN was linear with doses from 0 to 30 mg/kg for all four of the phenotypic markers employed. In addition, while PB administration stimulated the growth of all AHF phenotypes, the growth of a subset of AHF that expressed the widest variation in preneoplastic markers was specifically enhanced by PB administration.

Quantitative image cytometry of hepatocytes expressing gamma-glutamyl transpeptidase and glutathione S-transferase in diethylnitrosamine-initiated rats treated with phenobarbital and/or phthalate esters.

Image cytometry was used to quantify the volume of liver expressing two histochemical markers associated with neoplasia, gamma-glutamyl transpeptidase (GGT) and the placental isozyme of glutathione S-transferase (GST-P). Rats were treated with diethylnitrosamine (DENA) followed by phenobarbital (PB), di(2-ethylhexyl)phthalate (DEHP), or di-n-octyl-phthalate (DOP) for 26 weeks. In one series, PB-treated rats were given 2.0%, 0.5%, or 0.1% DEHP in the feed. GGT expression was detected diffusely throughout the liver parenchyma in several treatment groups so that any enhanced expression in altered foci (AF) and nodules (N) was not apparent. GST-P was detected only in AF and N. GST-P may represent a second genetic alteration, as GST-P+ AF and N also expressed GGT but not the reverse. The peroxisome proliferator DEHP inhibited expression of GGT or GST-P in livers of either DENA-treated or DENA+PB-treated rats. With GST-P the reduction was correlated to a reduced number of AF and N. In contrast, DEHP's stereoisomer, DOP, was as effective as PB in promoting expression of both markers. We conclude that image cytometry of hepatocytes expressing GST-P can be used in the bioassay of the carcinogenic potential of chemicals that affect liver proliferation.

Elevated extracellular Ca 2+ levels induce type X collagen synthesis in chondrocyte cultures

In 1930 the determination of serum alkaline phosphatase in patients with bone or liver disease ushered in the era of clinical enzymology. The association of elevated (bone) alkaline phosphatase in serum of patients with osteogenic sarcoma was the first evidence that tumor cells themselves produced the enzyme. It became clear, however, in the 1960s that the serum alkaline phosphatase was not a single enzyme but consisted of a family of isozymes originating from liver, bone, intestine, and placenta. This was a consequence of the introduction of a combination of electrophoretic separations, heat inactivation, and organ-specific amino acid inhibitors. This combination of measurements made possible the demonstration of a serum alkaline phosphatase of lung cancer origin, as confirmed by the histochemical visualization in lung cancer of the Regan Isozyme (placental alkaline phosphatase-PLAP). At present, the measurement of PLAP has its greatest utility as a tumor marker in seminoma and ovarian cancer. A PLAP-like isozyme in normal testis and ovary is expressed in these and other neoplasias and appears to be related to rare alleles of placental alkaline phosphatase. Current studies have utilized a panel of monoclonal antibodies to detect useful epitopes that suggest that PLAP and PLAP-like isozymes are coded by different genes. The PLAP gene has now been cloned and sequenced by Millan and others. This fundamental new information is providing a base line that will make it possible to explain the overlapping specificities of intestinal and placental isozymes, the degree of uniqueness of the PLAP-like isozyme, the precise mechanism of uncompetitive inhibition by L-phenylalanine and the evolutionary history of the alkaline phosphatases. Tumor PLAP is an example of oncotrophoblast gene expression.

Search for Epitopic Sites of Antibodies to Germ Cell Alkaline Phosphatase

This study comprises a search for epitopic sites of the germ cell alkaline phosphatase by the use of polyclonal and monoclonal antibodies. The aim of this study was to define epitopes of the germ cell alkaline phosphatase molecule by synthetic peptides representing the known sequence of the molecule. The amino acid sequences of the epitopes to which antisera react were not known. We used overlapping peptides covering the whole 532 amino acid germ cell alkaline phosphatase molecule, including the signal 19 amino acid peptide. A polyclonal, and three monoclonal, antibodies known to react equally well with placental alkaline phosphatase isozyme (PLAP), but which differ in their reactivities with the germ cell alkaline phosphatase isozyme, were used. We have revealed potential epitopic sites of the germ cell alkaline phosphatase molecule using first polyclonal anti-PLAP, followed by monoclonal antibodies for the mapping. We could also show that the antibodies exhibited higher reactivities with such sites if they were combined in a linear synthesis. This indicates that the germ cell alkaline phosphatase molecule has discontinuous epitopes.

Alkaline phosphatase isozymes: recent progress

The past few years have witnessed the reports of significant new events in alkaline phosphatase (AP) isozymes. The cloning of the relevant genes and their nucleotide sequencing have all been accomplished. As a group, the genes for the intestinal, germ cell and placental isozymes have considerable sequence similarity; it is noteworthy that they occupy vicinal positions on chromosome 2, while the tissue unspecific AP gene is located on chromosome 1. The latter makes evolutionary lineage and instances of coordinate expression understandable. Another new development is the demonstration of a phosphatidyl inositol glycan tail on the C-terminus of these chromosome-2 AP genes. This is the major membrane insertion mechanism for AP, which is a cell surface membrane enzyme. This information may be helpful in understanding the phenomenon of the depletion of intestinal mucosal AP during fat absorption. Finally, a discussion has been focussed on recent studies on seminoma and AP, including immunodetection and immunoradiotherapy.

Placental-like alkaline phosphatase from ovary and ascites of a patient with a malignant ovarian tumour

Human placental alkaline phosphatase (PLAP, EC 3.1.3.1) is present on the syncytiotrophoblast membrane from the 12th week of pregnancy. Several tumour cell lines also express PLAP or the closely related PLAP-like enzyme [l]. Trace expression of these isozymes is normally seen in some tissues such as testis, lung, and thymus [2,3]. The tumour-derived isozymes are known to differ biochemically somewhat from the placental isozyme, and the tumour-derived enzymes are referred to as PLAP-like enzymes. Recently, the cloning of cDNAs from the tissue-unspecific type (AP) [4], intestinal type (IAP) [5], and PLAP [6], and also the PLAP-like or the seminoma-derived Nagao isozyme were reported, revealing 98% homology between PLAP and the PLAP-like enzyme [7]. In patients with ovarian tumours, elevated levels of PLAP or the PLAP-like enzymes have been reported [l]. It is still, however, unclear which of these isozymes that are expressed. By use of mAbs with defined epitope specificity, possible immunochemical and conformational differences of PLAP and the PLAP-like isozymes may be identified (8,9].

Purification and partial characterization of the placental-like alkaline phosphatase in human lung tissue

Tumour associated alkaline phosphatase related to the placental isozyme was first described in a patient with small cell cancer of the lung by Fishman et al. [l] and named Regan isozyme. This finding had a significant impact on the future work in oncodevelopmental biology and later on, the Nagao [2] and Kasahara isozymes [3] were discovered in sera from patients with cancer. Recently, it has become clear that trace amounts of placental-like alkaline phosphatases are normally found in several tissues such as testis [4], non-malignant endocervix [5], lung and thymus [6]. The expression of isozymes related to the placental alkaline phosphatases during malignancy may be the result of an enhanced eutopic expression of a gene already transcribed and translated in the tissue of the origin [7]. The appearance of significantly elevated levels of placental-like alkaline phosphatases in healthy nonpregnant individuals is a strong indicator of an underlying malignancy, but also smoking causes a slight increase which may interfere with the clinical evaluation of placental-like alkaline phosphatase as a tumour marker. The increased serum levels of placental-like alkaline phosphatase as well as the elevated levels of CEA in smokers comparing with healthy controls indicate that this phosphatase isozyme is, in fact, derived from the lung tissue [8]. The normal lung may thus express eutopically trace amounts of this phosphatase isozyme, an expression which is enhanced by smoking. The clinical use of PLAP and the PLAP-like isozyme as diagnostic tools is not so widespread as markers like CPA, a-fetoprotein and others, because the frequency of elevated serum samples of phosphatase isozymes is low. The incidence of raised serum levels of placental and placental-like alkaline phos-

Reversible Alteration in the Expression of the Gap Junctional Protein Connexin 32 During Tumor Promotion in Rat Liver and Its Role during Cell Proliferation

Although numerous biochemical markers can identify putative preneoplastic altered hepatic foci (AHF) in rat liver, no consistent pattern of expression during hepatocarcinogenesis has emerged. Using quantitative stereologic analyses we demonstrated that decreased expression of the major hepatocyte gap junction protein, connexin 32 (Cx32), in rat AHF is a consistent observation in several protocols of multistage hepatocarcinogenesis. This change was observed after initiation by either ethylnitrosourea (ENU) or diethylnitrosamine (DEN), followed by promotion with phenobarbital (PB), dioxin, chlorendic acid, C.I. Solvent Yellow, or tamoxifen. AHF generated by Wy-14,643, ciprofibrate, and a choline/methionine-deficient dietary regimen also showed decreased Cx32 expression. The decrease of Cx32 in AHF was rapidly reversible after withdrawal of PB, and this change preceded a reduction in placental isozyme of glutathione-S-transferase (GST) expression in the same AHF. Within 20 days of withdrawal, fewer than 4% of GST-positive AHF were Cx32 deficient, while the volume of total AHF decreased 30%. Chronic PB treatment also resulted in a reversible decrease in Cx32 specifically in mid- and centro-lobular hepatocytes. Continuous thymidine labeling demonstrated that Cx32 could be uncoupled from the cell cycle, suggesting that some liver promoters may act directly to alter the expression of Cx32. These observations suggest that a decrease in Cx32 content was a relatively common epigenetic change in AHF induced during hepatocarcinogenesis by a number of initiating and promoting agents but that this change was not sufficient for carcinogenesis. This change, however, may be necessary for the mechanism(s) of tumor promotion, since Cx32-positive AHF did not proliferate as readily as Cx32-deficient AHF.

Expression of the Germ Cell Alkaline Phosphatase Gene in Human Choriocarcinoma Cells

Alkaline phosphatase (ALP) in human choriocarcinoma cells (malignant trophoblasts) was characterized by its greater sensitivity to EDTA and L-leucine inhibition as compared with the placental isozyme. In addition, both the fully processed and the nonglycosylated forms of choriocarcinoma ALP migrated faster than the corresponding placental enzyme in sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Choriocarcinoma cells express a 2.6-kilobase (kb) ALP mRNA unlike normal human placenta which expresses a 2.8-kb ALP mRNA. Administration of sodium butyrate to choriocarcinoma cells greatly increased the steady-state levels of the 2.6-kb choriocarcinoma ALP mRNA, which resulted in an increase in enzyme activity and biosynthesis. S1 nuclease analysis using probes derived from a placental ALP cDNA and ribonuclease protection assays employing probes derived from the germ cell ALP gene demonstrated that choriocarcinoma cells express the germ cell ALP gene. The germ cell ALP gene encodes the placental ALP-like isozyme that is primarily expressed in the thymus, testis, and germ cell tumors. The structures of the internal exons (II-X) of the germ cell ALP gene were determined previously based on their similarity to the placental ALP gene. However, the boundaries of exons I and XI (3' exon) of the germ cell ALP gene were not defined due to sequence divergence between the two genes at the 5' and 3' regions. Ribonuclease protection and primer extension assays demonstrated that exon I of this gene is 119 base pairs in length and that germ cell ALP mRNA contains one major transcription initiation site. The isolation and characterization of germ cell ALP cDNA clones from a butyrate-treated choriocarcinoma cDNA library showed that the germ cell ALP mRNA is 2487 bases in length and exon XI of this gene is 1135 base pairs long.

Modulation of glycoprotein hormone α-subunit levels, alkaline phosphatase activity, and DNA replication by antimetabolites in HeLa cultures

Synthesis of the glycoprotein hormone common α-subunit and alkaline phosphatase (placental isozyme) has been examined in HeLa S 3 cells. A variety of compounds that inhibit DNA synthesis lead to the increased production of both proteins. Experiments presented in this communication were undertaken to determine whether protein induction and DNA synthesis inhibition are coordinated. In general, nucleoside analogs and compounds that alter deoxynucleotide metabolism were good inducers of these ectopic products, whereas agents that altered DNA by intercalation, crosslinking, and covalent modification were poor inducers. The former class of effectors includes 5-bromo-2′-deoxyuridine, 5-fluoro-2′-deoxyuridine, 2′-deoxythymidine, 1-β- d-arabinofuranosylcytosine, methotrexate, hydroxyurea, N-phosphonoacetyl- l-aspartic acid, and sodium butyrate; and the latter class of compounds includes ethidium bromide, acridine, bleomycin, mitomycin C, cesalin, macromomycin, and cis-diamminedichloroplatinum(II). A direct correlation between protein induction and DNA synthesis inhibition is unlikely based on the following observations: (i) for some effectors, the concentrations required to induce α-subunit and PAP were significantly different from those necessary to inhibit DNA synthesis; (ii) several agents inhibit DNA replication but do not enhance hormone or enzyme production; (iii) the kinetics of ectopic protein induction were similar for a number of inducers whereas the kinetics of DNA synthesis inhibition elicited by the same compounds were quite different. It is difficult from the data obtained, however, to rule out the possibility that inhibition of DNA synthesis may be required but is not sufficient for protein induction.

Significance of alkaline phosphatase isozymes in the monitoring of patients with colorectal carcinoma.

The clinical course of colorectal carcinoma may be monitored by tumor markers such as carcinoembryonic antigen (CEA), carcinoma antigen (CA) 19-9 and CA-50. Alkaline phosphatase isozymes were previously used to study the clinical course of testicular and gynecologic tumors. In this study we investigated 8 patients with advanced colorectal carcinoma. Their sera were analyzed for the tumor markers CEA, CA 19-9, CA-50 and three alkaline phosphatase isozymes: the nonspecific liver isozyme LAP, the intestinal isozyme IAP and the placental isozyme PLAP. Rising levels of CEA, CA 19-9 and CA-50 were seen as expected, and PLAP also showed rising levels during tumor progression. LAP remained elevated. This indicates an association between progression of colorectal carcinoma and a raised serum content of alkaline phosphatase isozymes.

Regulation of the expression of some genes for enzymes of glutathione metabolism in hepatotoxicity and hepatocarcinogenesis

The reversible stage of tumor promotion, which follows the stage of initiation and precedes that of progression in multistage carcinogenesis, is a unique example of reversible toxicity in biological systems. In order to study the molecular mechanisms involved in the action of promoting agents during this stage, the regulation of the expression of genes for two enzymes of glutathione metabolism, γ-glutamyl transpeptidase (GGT) and the placental isozyme of glutathione S-transferase (GST-P), was studied under several different conditions of promotion during multistage hepatocarcinogenesis in the rat. Promotion by phenobarbital caused an increased expression of both of these genes in altered hepatic focal lesions, although this was somewhat more variable in the case of the GGT gene. C.I. Solvent Yellow 14, an industrial dye, served as an effective promoting agent. Feeding this dye resulted in a dramatic increase in the expression of GST-P, but not that of GGT in altered hepatic foci. Factors in crude, cereal-based diets inhibited the stage of promotion by diethylnitrosamine, but enhanced promotion by phenobarbital in a synergistic manner. In contrast, at least one purified diet had the converse effect during this stage. The mRNA levels of GST-P were uniformly elevated dramatically in reversible nodules and neoplasms of rat liver that had been induced by diethylnitrosamine and phenobarbital promotion. In contrast, the level of GGT mRNA was somewhat variable, with an occasional neoplasm exhibiting almost a background level of expression of this gene. Therefore, the altered regulation of multiple genes in hepatocytes during the stage of promotion can vary with the promoting agent itself; this process may be related to the heterogeneous gene expression seen in hepatic neoplasms. A possible role for specific DNA sequences in the 5′ flanking regions of such genes is considered. In addition, a cDNA clone to the mRNA of human liver GGT was isolated and sequenced. The homology of the coding sequence of the human liver GGT mRNA to that of rat kidney GGT mRNA was striking.

Evidence for the expression of a primitive intestinal-like alkaline phosphatase in the intestinal 407 cell line

Intestinal-like alkaline phosphatase was found to be expressed in the intestinal 407 cell line. This enzyme was identified by use of monoclonal antibodies specific for human placental (H7 and HPMS-1) and intestinal alkaline phosphatase (2HIMS-1 and 2HIMS-3) separately. Purification of this isozyme by use of two different monoclonal antibody immunoaffinity chromatographies demonstrates a single protein band on SDS-polyacrylamide gel electrophoresis indicating that this enzyme is not formed as a heterodimer. The apparent monomer subunit molecular weight and the dimer molecular weight of this isozyme were determined to 70000 and 160000, respectively. The enzyme is a homodimer according to molecular weight determinations. Furthermore, this isozyme is neuraminidase sensitive and comparatively heat stable, properties also characteristic for the placental enzyme. Our data suggest that the intestinal-like alkaline phosphatase in the intestinal 407 cell line displays properties intermediate of the intestinal and placental isozymes which may reflect the existence and reexpression of a new primitive isozyme.